Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort.

International urology and nephrology·2026
Same author

Safety and efficacy of navigable suction-assisted ureteral access sheath for treatment of kidney stones.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Same author

Efficacy and Safety of Rezūm Water Vapor Thermal Ablation in Large and Small Prostates: A Multicenter Comparative Analysis of 2,725 Patients.

Journal of the American College of Surgeons·2026
Same author

Body mass index and sperm morphology as independent predictors of increased sperm DNA fragmentation after cryopreservation in men with severe oligoasthenoteratozoospermia.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Same author

Next-generation imaging in prostate cancer.

Frontiers in urology·2026
Same author

Comparative outcomes of focal HIFU versus active surveillance in low- and intermediate-risk localized prostate cancer: a 75-month retrospective cohort study.

Frontiers in urology·2026
Same journal

Predicting Post-Radiotherapy Lymphocyte Recovery for Individualized Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma.

Current oncology (Toronto, Ont.)·2026
Same journal

From Adjunct to Essential: Integrating Supportive Care into Oncology.

Current oncology (Toronto, Ont.)·2026
Same journal

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.

Current oncology (Toronto, Ont.)·2026
Same journal

The Route of Administration Determines the Efficacy of Zinc in Preventing Radiation-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.

Current oncology (Toronto, Ont.)·2026
Same journal

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Current oncology (Toronto, Ont.)·2026
Same journal

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Current oncology (Toronto, Ont.)·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.4K

Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.

Lucas Resende Salgado1, Osama Zaytoun1, Ahmed Rabie2

  • 1Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA.

Current Oncology (Toronto, Ont.)
|April 27, 2026
PubMed
Summary
This summary is machine-generated.

Definitive chemoradiotherapy shows promise for high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy. This bladder-preserving approach offers comparable survival to surgery but requires further randomized trials.

Keywords:
NMIBCbladder cancerbladder preservationchemoradiotherapyradiotherapy

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.2K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

20.8K

Related Experiment Videos

Last Updated: Apr 28, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.4K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.2K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

20.8K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urologic Oncology

Background:

  • Non-muscle-invasive bladder cancer (NMIBC) has high recurrence and variable progression risks.
  • Standard treatment (TURBT + intravesical therapy) has limitations for high-risk/BCG-unresponsive disease.
  • Radiotherapy (RT) with chemotherapy is explored as a bladder-preserving alternative.

Purpose of the Study:

  • To review the role of definitive RT in high-risk NMIBC, focusing on T1 disease.
  • To evaluate outcomes of RT-based bladder-preserving strategies.
  • To assess the potential of chemoradiotherapy as an alternative to radical cystectomy.

Main Methods:

  • Narrative review of retrospective series, prospective trials, and meta-analyses.
  • Data extraction on TURBT extent, concurrent chemotherapy, RT techniques, volume, and dose.
  • Examination of contemporary guideline recommendations.

Main Results:

  • Concurrent chemoradiotherapy after maximal TURBT yields complete response rates of 80-88%.
  • Phase II trial (NRG/RTOG 0926) showed an 81% complete response rate in recurrent high-risk T1 disease.
  • Meta-analysis suggests ~54% 5-year recurrence-free survival and ~70% overall survival, with limited evidence.

Conclusions:

  • Definitive chemoradiotherapy is a promising investigational option for select NMIBC patients.
  • Consideration is recommended for patients unfit for or declining radical cystectomy.
  • Prospective randomized studies are essential to define its role in current NMIBC management.